Cosette Pharmaceuticals Launches First Injectable Product - Prochlorperazine Edisylate Injection in the U.S.

Rhea-AI Summary

Cosette Pharmaceuticals has launched Prochlorperazine Edisylate injection, marking its first injectable product introduced in the U.S.. This product is the generic version of Compazine® Injection, with an annual sales estimate of approximately $15M as of December 2021. The launch aligns with the company's strategy to diversify its offerings and enhance its portfolio, complemented by the recent acquisition of eight branded products from Daiichi Sankyo. Prochlorperazine is primarily used for severe nausea and vomiting and for treating schizophrenia.

Positive

• Launch of Prochlorperazine Edisylate injection diversifies product offerings.
• First injectable product for Cosette, enhancing market presence.
• Annual sales for Prochlorperazine Edisylate estimated at $15M as of December 2021.
• Recent acquisition of eight branded products from Daiichi Sankyo supports growth strategy.

Negative

• None.

Launch Further Diversifies Cosette’s Product Offerings In-Line with Growth Strategy

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Cosette Pharmaceuticals, Inc., a New Jersey-based pharmaceutical company, today announced the launch of Prochlorperazine Edisylate injection, 10 mg/2ml (5mg/ml).

Prochlorperazine Edisylate (Photo: Business Wire)

“This is the first injectable product Cosette has marketed in the U.S. and further exemplifies our strategy to expand and diversify Cosette’s portfolio of offerings,” said Apurva Saraf, Cosette’s President and CEO. “This In-licensed product, along with our recent acquisition of eight branded products from Daiichi Sankyo, delivers on our goal of supplementing our internal R&D efforts by acquiring and integrating strategically aligned product portfolios into our business, allowing Cosette to bring an array of new and important medications to U.S. patients and prescribers”

Prochlorperazine Edisylate Injection 10mg/2ml (5mg/ml) is the generic equivalent for Compazine® Injection 10mg/2ml (5mg/ml). According to IQVIA®, annual sales for Prochlorperazine Edisylate for 12 months ended December 2021 were approximately $15M.

Prochlorperazine Edisylate is used to control severe nausea and vomiting. Prochlorperazine Edisylate is also used for the treatment of schizophrenia. See Boxed Warning: WARNINGS. See Package Insert (PI) for full prescribing information including Safety Information:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4687b9f5-2d67-4fe0-af4d-2415a42b5292&audience=consumer

About Cosette Pharmaceuticals, Inc.:

Cosette Pharmaceuticals, Inc. is a US-based, fully integrated pharmaceutical company with capabilities in product development, manufacturing, and commercial operations. The current products focus on complex dosage forms including topical creams, ointments, oral liquids/solutions, suppositories, and

injectables. Cosette has a long history of quality manufacturing, consistent supply, and commercialization success, including two sites (New Jersey and North Carolina) supported by more than 300 dedicated employees across all functional areas. Cosette is backed by Avista Capital Partners, a healthcare focused private equity firm.

For more information, please visit: www.cosettepharma.com and follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220222005360/en/

Serge Ilin-Schneider: bd@cosettepharma.com

Kian Kazemi: sales@cosettepharma.com

Media:

Lynn Munroe: EGCPR@egcgroup.com

Source: Cosette Pharmaceuticals, Inc.

FAQ

What is Prochlorperazine Edisylate injection and its purpose?

Prochlorperazine Edisylate injection is a medication used to control severe nausea and vomiting and to treat schizophrenia.

What are the sales figures for Prochlorperazine Edisylate?

The annual sales for Prochlorperazine Edisylate were approximately $15M for the 12 months ending December 2021.

What strategic moves has Cosette Pharmaceuticals made recently?

Cosette Pharmaceuticals launched Prochlorperazine Edisylate injection and acquired eight branded products from Daiichi Sankyo to diversify its product portfolio.

Why is the launch of Prochlorperazine Edisylate significant for Cosette Pharmaceuticals?

This launch is significant as it marks Cosette's first injectable product in the U.S., aligning with its strategy to expand and diversify its offerings.